ICON
ICON is recorded as a service provider in 1,255 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 1,255 trials · Latest update first
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
Sponsor Taiho Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The planned Phase 1 Part 3 dose-expansion and Phase 2 portions were not conducted because of early trial termination.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor Bioinvent International AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 12 centers in Europe and the United States, of which 8 centers enrolled participants.
- Forty-two participants were screened by 9 sites, and 35 participants were enrolled over approximately 16 months.
- The planned Phase 2a part was not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Non-Randomized, Open-Label, Non-Controlled, Adaptive, Multiple-Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Zosurabalpin Following Intravenous Administration In Healthy Participants
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 35 healthy subjects at one investigative site in the Netherlands between 18 October 2023 and 28 March 2024.
- All subjects in the 1500 mg/Q12h cohort discontinued before Day 10, precluding Day 10 pharmacokinetic assessments for this cohort.
- A protocol amendment added ultrasound inspection at follow-up after PICC-line removal to monitor safety and well-being.
These findings describe the trial, not the service provider’s performance or responsibility.
Single-Center, Open-Label, Single-Arm Study to Investigate the Excretion Balance, Absolute Bioavailability, and Metabolite Profile of 60 mg [14C]-Alogabat administered Orally as Capsule Together with an Intravenous Microdose of 100 μg [13C]-Alogabat in Healthy Male Participants
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- The study enrolled 8 healthy participants at a single investigative site in the Netherlands from 11 January 2024 to 15 March 2024.
These findings describe the trial, not the service provider’s performance or responsibility.
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
Sponsor Mirati Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures
Sponsor Sk Life Science Inc.
- Start (EU)
- Latest update
- Estimated end
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the pediatric ORION-16 , ORION-13, ORION-20, or ORION-19 studies (VICTORION-PEDS-OLE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ICON?
The 2026-10-09 snapshot links ICON to 1,255 distinct CTIS trials. Recorded services include Laboratory services, Clinical monitoring, Regulatory services, Project management, among 480 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ICON?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Haematological Malignancies, Gastroenterology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ICON conducted?
The linked trials record locations in 31 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where ICON delivered services.
What can this page tell me about ICON's trial experience?
Browse 1,255 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 42 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 29 recorded name variants under ICON. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ICON
- ICON Bioanalytical Laboratories
- ICON Bioanalytical Laboratory
- ICON Bioanalytical Labs
- ICON Central Lab
- ICON Clinical Research Germany GmbH
- ICON Clinical Research ICON IDEA
- ICON Clinical Research Limited
- ICON Clinical Research Limited Ireland Filial
- ICON Laboratory Services, Inc.
- ICON Medical Imaging
- ICON PLC
- ICON clinical Research Ltd.
- ICON plc
- Icon
- Icon (Lr) Limited
- Icon Clinical Research (U.K.) Limited
- Icon Clinical Research GmbH
- Icon Clinical Research LLC
- Icon Clinical Research Limited
- Icon Clinical Research Ltd
- Icon Clinical Research S.A.R.L.
- Icon Development Solutions LLC
- Icon Development Solutions Limited
- Icon Laboratories Inc.
- Icon Laboratory Services Inc.
- Icon Medical Imaging
- Icon PLC
- Icon Public Limited Company